SCHEMBL10133097

SCHEMBL10133097

[O-][S+](Cc1ccc(-c2ccccc2)cn1)NCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.43
HIF1A Q16665 4/20 0.38
HPGDS O60760 2/20 0.35
TUBB4A P04350 2/20 0.35
TUBB P07437 2/20 0.35
TUBA3C P0DPH7 2/20 0.35
TUBA1B P68363 2/20 0.35
TUBA4A P68366 2/20 0.35
TUBB4B P68371 2/20 0.35
TUBB3 Q13509 2/20 0.35
TUBB2A Q13885 2/20 0.35
TUBB8 Q3ZCM7 2/20 0.35
TUBA3E Q6PEY2 2/20 0.35
TUBA1A Q71U36 2/20 0.35
TUBA1C Q9BQE3 2/20 0.35
TUBB6 Q9BUF5 2/20 0.35
TUBB2B Q9BVA1 2/20 0.35
TUBB1 Q9H4B7 2/20 0.35
ABL1 P00519 1/20 0.35
LYN P07948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10133107 0.79 RAB9A (0.47) HDAC3HDAC1HDAC2HDAC6ALDH1A1
SCHEMBL10133086 0.77 HIF1A (0.41) SRCHIF1ARAB9ANPC1NFKB1
SCHEMBL28665142 0.73 IDO1 (0.44) ALDH1A1GAAMEN1KMT2ACYP3A4
SCHEMBL10133077 0.73 GAA (0.51) SRCHIF1AGAAMEN1KMT2A
SCHEMBL27843023 0.71 HIF1A (0.49) SRCHIF1ARAB9ACYP1A2CYP2D6
SCHEMBL10133084 0.71 CA2 (0.48) SRCHIF1AALDH1A1LMNASMN1; SMN2
SCHEMBL31380221 0.70 SRC (0.79) SRCHPGDSTUBB4ATUBBTUBA3C
SCHEMBL10133069 0.67 SRC (0.67) SRCHIF1ATUBB4ATUBBTUBA3C
SCHEMBL25304675 0.67 RAB9A (0.45) SRCHIF1AALDH1A1RAB9ALIPG
SCHEMBL2554715 0.67 RAB9A (0.45) SRCHIF1AALDH1A1RAB9ALIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 SRC 68/4885HIF1A 1753/4885HPGDS 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.